Загрузка страницы

IP Biotech adviser assures of India's Covaxin's safety, efficacy as PH gov't eyes its procurement

Headstart: IP Biotech scientific adviser Dr. Noel Miranda assures of the safety and efficacy of COVAXIN, the COVID-19 vaccines made by India-based Bharat Biotech. He says the vaccine uses inactivated virus which has been proven reliable through the years. He adds the vaccine has an 81% efficacy, but he says more detailed findings are due out this week. The Philippines is in talks with India for the procurement of 10 to 20 million doses of the COVAXIN. IP Biotech is the distributor of Bharat's vaccine.

For more more ANC news videos, click the link below:
https://www.youtube.com/playlist?list=PLm34qRgqWBU4Mvq4BSrOawikENaFf38wn

To watch Headstart videos, click the link below:
http://bit.ly/ANC_Headstart

To watch The World Tonight videos, click the link below:
http://bit.ly/ANC_TheWorldTonight

Subscribe to ANC YouTube channel!
Click here: http://bit.ly/ANC24-7

Visit our website at https://news.abs-cbn.com/anc
Facebook: https://www.facebook.com/ancalerts
Twitter: https://twitter.com/ancalerts

#ANCHighlights
#ANCAlerts
#ANCNews

Видео IP Biotech adviser assures of India's Covaxin's safety, efficacy as PH gov't eyes its procurement канала ANC 24/7
Показать
Комментарии отсутствуют
Введите заголовок:

Введите адрес ссылки:

Введите адрес видео с YouTube:

Зарегистрируйтесь или войдите с
Информация о видео
9 марта 2021 г. 8:38:25
00:20:18
Другие видео канала
PH Testing Chief: We aim to inoculate up to 350,000 per day when bulk of vaccines arrive | ANCPH Testing Chief: We aim to inoculate up to 350,000 per day when bulk of vaccines arrive | ANCYalda Hakim with Sadhguru on Religion, Politics & Human SocietyYalda Hakim with Sadhguru on Religion, Politics & Human SocietySabarimala & Triple Talaq: Different case studies for gender equality in India|Arth - A Culture FestSabarimala & Triple Talaq: Different case studies for gender equality in India|Arth - A Culture FestAnalyst: If PSEi follows charts, we may see another opportunity in crisis valuations like last yearAnalyst: If PSEi follows charts, we may see another opportunity in crisis valuations like last yearPak must accept J&K as part of India & India handling of China is a lesson to world: Ashley TellisPak must accept J&K as part of India & India handling of China is a lesson to world: Ashley TellisA Virologist Explains What Covaxin's 81 Per Cent Efficacy Data Means For Us | The QuintA Virologist Explains What Covaxin's 81 Per Cent Efficacy Data Means For Us | The QuintNews on the Hour | India crosses 2.30 crore COVID vaccination, PM Modi to inaugurate Maitri SetuNews on the Hour | India crosses 2.30 crore COVID vaccination, PM Modi to inaugurate Maitri SetuWhy U.S. Malls Are DisappearingWhy U.S. Malls Are DisappearingCovishield Vs Covaxin: Similarities And Differences Between India's Covid Vaccines | Explained ITCovishield Vs Covaxin: Similarities And Differences Between India's Covid Vaccines | Explained ITTake Second Covishield Jab After 28 Days, it's Safe, Practical, Simple; Don't Delay—Dr Shahid JameelTake Second Covishield Jab After 28 Days, it's Safe, Practical, Simple; Don't Delay—Dr Shahid JameelAIIMS Director On Why COVID-19 Cases Are Rising In IndiaAIIMS Director On Why COVID-19 Cases Are Rising In IndiaIndian envoy to PH: Discussions ongoing for at least 8 million doses Covaxin deal with PH | ANCIndian envoy to PH: Discussions ongoing for at least 8 million doses Covaxin deal with PH | ANCTrump v Biden: The Final DebateTrump v Biden: The Final DebateSambit Patra slams Opp'n over politics on COVAXIN; cites efficacy data, PM's inoculationSambit Patra slams Opp'n over politics on COVAXIN; cites efficacy data, PM's inoculationLife in the Philippines pt 1 | A Foreigner's PerspectiveLife in the Philippines pt 1 | A Foreigner's PerspectiveIsko Moreno explains why he put  several barangays under lockdown | ANCIsko Moreno explains why he put several barangays under lockdown | ANCCovaxin Interim Results 'Encouraging', Phase 3 Trials To Continue: AIIMS ChiefCovaxin Interim Results 'Encouraging', Phase 3 Trials To Continue: AIIMS ChiefCovaxin maker can allocate at least 10M COVID-19 vaccine doses for PH - distributor | ANCCovaxin maker can allocate at least 10M COVID-19 vaccine doses for PH - distributor | ANCWhat are the side effects of the two COVID-19 vaccines rolled out in India?What are the side effects of the two COVID-19 vaccines rolled out in India?U.S. Official: Quad nations to announce financing to boost India vaccine output| ANCU.S. Official: Quad nations to announce financing to boost India vaccine output| ANC
Яндекс.Метрика